LBS1:01 Efficacy and safety of obinutuzumab in active systemic lupus erythematosus: topline results of the phase III ALLEGORY trial
Richard Furie, Maria Dall'Era, Edward M Vital, Jay P Garg et autres
Objectives Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody that induces potent and sustained B-cell depletion, is approved for active lupus nephritis. The Phase III, multicenter, randomized, double-blind, placebo-controlled ALLEGORY trial ( NCT04963296) evaluated obinutuzumab compared with placebo when added to standard …
us, gb, br, Afrique du Sud, pl, fr, it, nz, ca, ch (code pays fourni par la source)
0 citations